Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
AEON Biopharma (AEON): Can Analyst Targets of $1.65 Be Reached From Current Levels?

AEON Biopharma (AEON): Can Analyst Targets of $1.65 Be Reached From Current Levels?

Key Takeaways

  • The central target of $1.65 is the arithmetic mean of three verified, current analyst price targets ($1.20, $1.80, and $2.00).
  • With the stock near $0.15, reaching $1.65 would require a gain of roughly 1,000%, an exceptionally large move.
  • The analyst target range is wide—$1.20 to $2.00—reflecting genuine disagreement about funding, the regulatory path, and commercial potential.
  • The strongest supporting factor is renewed alignment with the FDA on a biosimilar regulatory pathway for ABP-450.
  • The biggest risks are severe funding uncertainty, a clinical-stage profile with no product revenue, and a share price that has fallen more than 80% over the past year.
  • Additional details on major news, price action, forecasts, and earnings are available on dedicated pages for AEON.

Analyst Price Targets and Consensus View

Three verifiable analyst price targets form the basis of the $1.65 central figure. Lake Street's Thomas Flaten reiterated a Buy and raised his target to $2.00 from $1.00 in early October 2026, citing the company's announced regulatory progress. Laidlaw's Yale Jen initiated coverage with a Buy and a $1.80 target in September 2026, framing ABP-450 as a mid-stage specialty pharmaceutical opportunity. H.C. Wainwright's Douglas Tsao kept a Buy but lowered his target to $1.20 from $5.00 in August 2026, explicitly citing funding uncertainty. The mean of these three targets is roughly $1.67, rounded to $1.65, with a range of $1.20 to $2.00.

The dispersion is meaningful. The highest targets lean on the value of a cleared regulatory pathway and eventual commercial launch, while the lowest reflects near-term balance-sheet risk. None of these figures is a guarantee, and the wide range signals that analysts are not in lockstep about the company's trajectory. I also checked this using Tickeron’s AI Screener to see how AEON compares to others in the industry.

Current Market Position and Path Toward the Target

At a price near $0.15, the required move to $1.65 is approximately 1,000%, which must be described as very large under any framework. AEON is a pre-revenue developer with no approved product, so the path is binary: the company must first secure funding to continue development, then advance ABP-450 through the clinic, and ultimately obtain regulatory approval and commercialize it. Each milestone is a separate point of potential failure or value creation, which is why the share price has been so volatile and why analyst targets sit so far above the market.

What Could Support a Move Toward the Target

The clearest positive signal is management's reported alignment with the FDA on key biosimilar pathway requirements for ABP-450, which improves the odds of a viable regulatory route. The company has also demonstrated cost discipline, with research and development (R&D) expenses declining materially year over year. If AEON secures additional financing, advances clinical milestones, or reports favorable regulatory feedback, sentiment could improve sharply from a depressed base. A modest market capitalization amplifies the percentage impact of any positive news.

What Could Prevent the Target From Being Reached

The principal obstacle is financing. Analysts have explicitly lowered targets on funding uncertainty, and without capital the development program cannot continue. AEON has no product revenue and reports losses, so it depends on dilutive equity raises or partnerships. The company also relies on Daewoong to manufacture ABP-450, creating supply-chain concentration risk. Clinical trials can fail, regulatory timelines can slip, and the stock's more than 80% decline over the past year reflects investor doubt that these hurdles will be cleared.

Technical Levels and Market Structure

The stock trades near its recent lows, with a 52-week range roughly between $0.15 and $1.45. A recovery toward $1.65 would require first reclaiming higher ground and breaking through a long-term downtrend. Round-dollar levels and prior consolidation zones, such as the area near $1.00 to $1.45, would represent potential resistance on any rebound. The low absolute price and elevated trading volume make the shares highly volatile and prone to outsized percentage swings.

Time Horizon and What Investors Should Monitor

Analyst price targets for AEON generally reflect a roughly 12-month research horizon, though horizons can differ between firms. Investors should watch for funding announcements, updates on the ABP-450 clinical program, any additional FDA guidance, and quarterly earnings releases that reveal cash runway and R&D spending. Changes in analyst ratings or targets often follow these catalysts and can move a thinly traded name quickly.

Leveraging AI Tools in My Research

I often rely on Tickeron's AI Daily Buy/Sell Signals to monitor volatile names like AEON. The platform uses artificial intelligence to track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For catalyst-driven stocks, these signals help me spot trend changes and complement my own analysis without replacing it.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AEON

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


AEON's Indicator enters downward trend

The Aroon Indicator for AEON entered a downward trend on November 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 177 similar instances where the Aroon Indicator formed such a pattern. In 157 of the 177 cases the stock moved lower. This puts the odds of a downward move at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEON as a result. In 60 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for AEON turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 27 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.

AEON moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AEON crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 58%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +14.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEON advanced for three days, in 161 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

AEON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.571) is normal, around the industry mean (3.592). P/E Ratio (-0.039) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. AEON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
5 Park Plaza
Phone
+1 949 354-6499
Employees
8
Web
https://www.aeonbiopharma.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
AEON Biopharma (AEON): Can Analyst Targets of $1.65 Be Reached From Current Levels?